US30052C1071 - Common Stock
EVOLUS INC
NASDAQ:EOLS (10/29/2024, 5:20:01 PM)
After market: 16.69 0 (0%)16.69
+0.42 (+2.58%)
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 279 full-time employees. The company went IPO on 2018-02-08. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
EVOLUS INC
520 Newport Center Dr Ste 1200
Newport Beach CALIFORNIA 92660
P: 19492844555
CEO: David Moatazedi
Employees: 279
Website: https://www.evolus.com
Here you can normally see the latest stock twits on EOLS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: